ArticleCancer management and research2025
Bioinformatics Analysis and Experimental Validation of Lactylation Related Genes in Lung Adenocarcinoma.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational protein lactylation modification in lung cancer: an emerging targeted therapeutic strategy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lactylation, a novel post-translational modification, is dysregulated in various tumors and influences lung cancer progression. However, its role in lung adenocarcinoma (LUAD) remains unclear. Based on multi-omics analysis results, this study investigated lactylation levels in LUAD tissues and explored the dual research positioning of lactylation as a prognostic marker and therapeutic target. Methods: Lactylation levels in LUAD tissue microarrays were assessed using immunohistochemistry and immunofluorescence. Western blot analysis validated these findings. Differential expression analysis of lactylation-related genes was conducted using The Cancer Genome Atlas (TCGA, n=365), based on |log2 fold-change (FC)|≥2. KEGG pathway analysis identified key biological pathways, and COX regression analysis pinpointed prognostic genes. Single-cell RNA sequencing data from the GEO database validated these genes, with mitochondrial gene threshold <20%. Results: Lactylation levels were significantly elevated in LUAD tissues compared to adjacent non-cancerous tissues, as shown by immunohistochemistry and confirmed by Western blot analysis. Differential analysis identified 17 lactylation-related genes enriched in pathways such as AMPK signaling and cellular senescence. COX regression analysis identified five risk genes: KIF2C, MKI67, HMGA1, PFKP, and CCNA2. Validation with single-cell RNA sequencing data revealed high expression levels of these genes in LUAD tissues and the LUAD cell line H1299. Functional validation revealed that the 5 genes panel significantly regulates global lactylation modification in vitro. Conclusion: LUAD tissues exhibit elevated lactylation levels, suggesting their potential as prognostic biomarkers. The identified genes-KIF2C, MKI67, HMGA1, PFKP, and CCNA2-are highly expressed in cancerous tissues and correlate with LUAD prognosis. These findings highlight their value as tumor biomarkers and therapeutic targets, offering new opportunities for targeted LUAD treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.